poznaisebya.com Report : Visit Site

Technical data of the poznaisebya.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host poznaisebya.com. Currently, hosted in Germany and its service provider is Hetzner Online AG .

the related websites

folowsite.com lv.com djpunjab.org.w3lookup.net 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx/1.12.2 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

home search stat log /* 728x15, */ • aerobics cardio [942] use of statins increases the risk of developing type 2 diabetes but reduces coronary events an article published online first and in an upcoming edition of the lancet reports that new research based on a meta-analysis of thirteen statin trials has shown that use of statins increases the risk of developing type 2 diabetes by 9 percent. still, the absolute risk is low, especially when compared with the beneficial effect that statins have on reducing coronary events. the article is the work of professor naveed satar and dr david preiss, glasgow cardiovascular research centre, university of glasgow, uk, and colleagues. trials of statin therapy on the risk of development of diabetes in patients given statins have had inconsistent findings. page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] [40] [50] [60] [70] [80] [90] • allergies [366] examining link between childhood asthma, sleep and school performance bradley hasbro children's research center and hasbro children's hospital researchers have received more than $2.5 million in direct costs from the eunice kennedy shriver national institute of child health and human development (nichd) to study the impact of asthma on the sleep quality and academic performance of young children. the five-year grant will allow pediatric researchers, led by daphne koinis-mitchell, phd, to evaluate the connection between asthma and allergic rhinitis symptoms (such as sneezing, congestion or a runny nose), sleep quality, and school functioning in urban, elementary school children between the ages of 7 and 9. page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] • alternative [414] study says lead may be the culprit in adhd adhd, or attention-deficit/hyperactivity disorder, is among the costliest of behavioral disorders. its combination of inattention, impulsivity and hyperactivity leads to accidental injuries, school failure, substance abuse, antisocial behavior and more. yet despite nearly a century of study, the disorder's roots remain mysterious. much of modern adhd research has focused on heritability of the condition, and indeed evidence suggests that genes may account for as much as 70 percent of hyperactivity and inattention in children. but that leaves 30 percent unexplained, so recently the focus has shifted to the environment. what is it that triggers an underlying susceptibility and changes it into a full-blown disorder? page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] [40] • anti aging [863] potential for a muscle-preserving therapy hey guys, remember the muscle shirts we wore in our teens and 20s? after the age of 40 that meager part of our wardrobes usually is obsolete. yes, at the big 4-0 we begin to lose muscle, and by age 80 up to a third of it may be gone. it's an inevitable process of aging called sarcopenia. why does sarcopenia happen and can it be stopped? a study conducted in mice with accelerated muscle loss at the university of texas health science center at san antonio provides this insight: less protection from antioxidants and more damage from oxidative stress results in impairment to cells' energy centers, which slowly leads to death of muscle cells. a team directed by holly van remmen, ph. page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] [40] [50] [60] [70] [80] • arthritis [505] designing easy-to-use products with the help of arthritis simulation gloves as the u.s. population ages, manufacturers of consumer goods are realizing that many customers may not be as nimble-fingered or sharp-sighted as they once were. to help product designers and engineers address those changing requirements, researchers at the georgia tech research institute (gtri) have been developing evaluation methods and design techniques to identify and address the needs of all consumers, including those with functional limitations. gtri's latest product is a pair of arthritis simulation gloves, which reproduce the reduction in functional capacity experienced by persons with arthritis. the gloves help those responsible for consumer products better understand how arthritis affects a person's ability to grasp, pinch, turn, lift and twist objects. page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] [40] [50] • back pain [338] soma 250 mg shown to significantly improve functionality and reduce disability in patients with low back pain in three days a recent analysis of two pivotal clinical trials in patients with acute low back pain (albp) who were treated with soma® (carisoprodol) 250 mg showed significantly improved functionality and reduced disability after three days of treatment, as measured by the roland-morris disability questionnaire (rmdq). this analysis is being presented this week at the 26th annual meeting of the american academy of pain medicine in san antonio, tx. in addition, a recent review of published literature indicates that soma 250 mg is the only skeletal muscle relaxant proven to significantly improve functionality in patients with acute low back pain as measured by the rmdq. page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] • beauty [650] walking linked to eased osteoarthritis "progressive walking" combined with glucosamine sulphate supplementation has been shown to improve the symptoms of osteoarthritis. researchers writing in biomed central's open-access journal arthritis research and therapy found that patients who walked at least two bouts of 1500 steps each on three days of the week reported significantly less arthritis pain, and significantly improved physical function. dr kristiann heesch worked with a team of researchers from the university of queensland, australia, to carry out the trial in 36 osteoarthritis patients (aged 42 - 73 years). all patients received the dietary supplement for six weeks, after which they continued to take the supplement during a 12-week progressive walking program. page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] [40] [50] [60] • depression [515] naurex inc. reports positive top-line phase i results for its novel mechanism nmda receptor modulator glyx-13 in treatment-resistant depression naurex inc., a clinical stage company developing innovative treatments for depression and other cns disorders based on its novel glycine site functional partial agonist (gfpa) nmda receptor modulators, today reported positive top-line results from its phase i clinical trial of lead compound glyx-13. glyx-13 is a gfpa selective modulator of the nmda receptor. it is initially being developed as a therapy for treatment-resistant depression in severely depressed patients. in the phase i trial, adverse events were similar for subjects receiving glyx-13 and placebo and were all rated as mild. there were no signs of the schizophrenia-like side effects associated with other nmda receptor modulator drugs. page: [01] [02] [03] [04] [05] [06] [07] [08] [09] [10] fast: [10] [20] [30] [40] [50] • diabetes [986] nice appraisal of liraglutide for type 2 diabetes the national institute for health and clinical excellence (nice) is currently appraising the use of liraglutide for the treatment of type 2 diabetes. liraglutide works by stimulating the release of insulin; it also reduces the appetite and therefore food intake by slowing gastric emptying. in preliminary recommendations published today (15 february 2010), nice has recommended liraglutide 1.2 mg daily as part of triple therapy regimens (in combination with metformin and sulfonylurea, or metformin and a thiazolidinedione) as an option for the treatment of type 2 diabetes, when control of blood glucose remains or becomes inadequate (hba1c 7. page: [001] [002] [003] [004] [005] [006] [007] [008] [009] [010] fast: [010] [020] [030] [040] [050] [060] [070] [080] [090] • diseases [1281] what is dengue fever? what

URL analysis for poznaisebya.com

http://poznaisebya.com/home-health-care/page_9.html
http://poznaisebya.com/home-health-care/page_50.html
http://poznaisebya.com/fitness-equipment/page_5.html
http://poznaisebya.com/veterinary-news/page_20.html
http://poznaisebya.com/gastroenterology-news/page_30.html
http://poznaisebya.com/nutrition/page_70.html
http://poznaisebya.com/gastroenterology-news/page_2.html
http://poznaisebya.com/physical-therapy/page_4.html
http://poznaisebya.com/public-health-news/page_4.html
http://poznaisebya.com/home-health-care/page_4.html
http://poznaisebya.com/pain-management/page_10.html
http://poznaisebya.com/psychology-news/page_80.html
http://poznaisebya.com/nutrition/page_8.html
http://poznaisebya.com/nutrition/page_2.html
http://poznaisebya.com/veterinary-news/page_7.html

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: POZNAISEBYA.COM
Registry Domain ID: 912737857_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.PublicDomainRegistry.com
Registrar URL: http://www.publicdomainregistry.com
Updated Date: 2017-03-28T08:36:27Z
Creation Date: 2007-04-06T15:11:56Z
Registry Expiry Date: 2018-04-06T15:11:56Z
Registrar: PDR Ltd. d/b/a PublicDomainRegistry.com
Registrar IANA ID: 303
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.2013775952
Domain Status: ok https://icann.org/epp#ok
Name Server: NS1.REIKI.IN.UA
Name Server: NS2.REIKI.IN.UA
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-10-02T15:48:54Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR PDR Ltd. d/b/a PublicDomainRegistry.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =poznaisebya.com

  PORT 43

  TYPE domain

DOMAIN

  NAME poznaisebya.com

  CHANGED 2017-03-28

  CREATED 2007-04-06

STATUS
ok https://icann.org/epp#ok

NSERVER

  NS1.REIKI.IN.UA 138.201.188.255

  NS2.REIKI.IN.UA 148.251.196.92

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .